ROCHE PREPARED TO FILE ACCELERATED APPROVAL NDA FOR SAQUINAVIR
ROCHE PREPARED TO FILE ACCELERATED APPROVAL NDA FOR SAQUINAVIR based on results from a Phase II trial of the HIV proteinase inhibitor in combination with Burroughs-Wellcome's Retrovir (zidovudine, AZT) and Roche's Hivid (zalcitabine, ddC) if FDA indicates that it believes such a filing is appropriate, the company said June 2. Results of the Phase II study, AIDS Clinical Trials Group protocol 229, were reported by the National Institute of Allergy & Infectious Diseases May 31.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth